奥曲肽治疗化疗相关性腹泻（最终版）.doc

Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article 奥曲肽治疗直肠癌患者化疗相关性诱发腹泻：综述 Abstract摘要 Background: Chemotherapy-induced diarrhea(CID)is well known in cancer management. The risk is greater when the primary cancer is colorectal. The article aims towards assessing the role of octreotide in CID through an extensive literature search. 背景：化疗相关性诱发腹泻(CID)在癌症治疗中比较常见。特别是原发灶位于直肠的癌症则风险更大。本文旨在通过全面的文献检索评价奥曲肽治疗CID的作用。 Methods：After searching through PBMED,MEDLINE and the Cochrane library, only those studies which were published over the last 20 years in English and where at least the majority of the cohort were colorectal patients, were included. Two randomized trials, four non-randomized studies and two case-series publications were thus considered. 方法：检索PUBMED,MEDLIN和循证医学图书馆，选出最近20年用英文发表的、并且至少所选的主要观察队列为结肠病人的研究论文。符合条件的共有两项随机对照试验，四项非随机研究和两篇系列案例研究文献。 Results: It was seen in both the randomized studies, that octreotide had much better outcome as compared to loperamide in treating severe CID. Among 88 patients from the non-randomized studies with severe CID, the primary cancer was colorectal in 79 patients.61 patients had drug-resistant CID. Within a maximum of 96 hours, octreotide reduced CID by ≥ 2 grades in 91% of 88 patients and in 88.52% patients with drug-resistant CID. 结果：随机对照试验研究结果显示，奥曲肽治疗严重CID的疗效比咯哌丁胺好很多。非随机研究结果显示，88例严重CID病人中，原发是结肠癌的有79例。其中61例病人有CID抗药性。用奥曲肽治疗最长时间为96个小时后，88例严重CID病人中，抗药性降低的患者为91%，抗药性患者中88.52%患者的CID评分至少2级。 Conclusion: Octreotide is effective in treating severe CID, resistant to other modes of treatment. It is associated with a few minor adverse effects. Though expensive, octreotide could be considered as first line medication in CID of grades 3 or above. Its use in lower grades of CID would not be cost effective. 结论：奥曲肽对其他治疗方式无效的严重CID患者有效，且不良反应较少。尽管价格比较昂贵，奥曲肽仍可考虑作为CID评分３级以上患者的一线药物。在低级别的CID治疗中，奥曲肽的作用并不是很大。 Key words: octreotide, chemotherapy induced diarrhoea, octreotide in diarrhoea. 关键词：奥曲肽，化疗导致的腹泻，奥曲肽治疗腹泻 Abbreviations缩写 CID =